Or -- the price is so beaten down that it's a great buy. I agree management has made mistakes. That's the bad part. The NSS is performing about twice as good as the FDA performance criteria. The clinical reversions is a non-issue. Not all patients convert. This is killing it over no treatment. And a patient yo-yo is normal. They are teetering on the edge. Probably due to details of their injury. This is a strong buy.
News 
Market Data 
Discover 
